Abattis Biologix Corporation (FLU - CNSX) Began Trading on the CNSX - InvestmentPitch.com Posts Video News Alert
(Thomson Reuters ONE) -
Vancouver, British Columbia, December 24, 2010 - Abattis Biologix Corporation
(FLU - CNSX) is the latest company to begin trading on the Canadian National
Stock Exchange, better known as the CNSX.
To view the InvestmentPitch.com video news alert about Abattis Biologix, click
here. If the link is unavailable, please visit www.InvestmentPitch.com and enter
"Abattis" in the search bar.
On April 16, 2009, the company entered into an agreement with PRB
Pharmaceuticals and Pacific Bio-Pharmaceuticals for the purchase of their
interest in patents and intellectual property related to antiviral products
designed to prevent avian influenza in humans and poultry. The company issued
25,000,000 common shares, assigned a value of $500,000, for this acquisition.
The Antiviral formulations were developed and designed to inhibit growth over
multiple segments of the influenza virus life cycle - viral binding, encoding,
replication, and release. To date, the company's research has shown the
formulations to be highly effective in reducing the severity and duration of
influenza illness symptoms in humans.
At present, the company is focused on refining and bringing to market a
proprietary nutraceutical formulation of botanical agents with demonstrated
ability to inhibit the growth of, and reduce the severity and duration of
various strains of human influenza and other viral diseseases. Continuing
research is being conducted at the Institute for Antiviral Research, Utah State
University.
Contact:
Abattis Biologix Corporation
Gil Scneider
604-484-5761
gil(at)abattis.com
InvestmentPitch.com
Barry Morgan, CFO
604-684-5524
bmorgan(at)investmentpitch.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: InvestmentPitch via Thomson Reuters ONE
[HUG#1475649]
Unternehmensinformation / Kurzprofil:
Datum: 25.12.2010 - 01:33 Uhr
Sprache: Deutsch
News-ID 50079
Anzahl Zeichen: 2450
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 437 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Abattis Biologix Corporation (FLU - CNSX) Began Trading on the CNSX - InvestmentPitch.com Posts Video News Alert"
steht unter der journalistisch-redaktionellen Verantwortung von
InvestmentPitch (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
